Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | PRKX | P51817 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695003 | 0.87 | S1PR1 (0.57) | ALOX5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8761070 | 0.85 | ALOX5 (0.58) | ALOX5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL696437 | 0.84 | ALOX5 (0.53) | ALOX5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL135151 | 0.83 | MRGPRX4 (0.53) | ALOX5MRGPRX4MAOBS1PR1PRKX | |
| SCHEMBL8588173 | 0.82 | LMNA (0.58) | ALOX5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL32675258 | 0.81 | LMNA (0.61) | ALOX5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL574143 | 0.81 | LMNA (0.61) | ALOX5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL9064977 | 0.81 | ALOX5 (0.50) | ALOX5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL16319058 | 0.81 | ALOX5 (0.53) | ALOX5LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL2212877 | 0.81 | ALOX5 (0.53) | ALOX5LMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| EP-1984363-A1 | TRIAZOLOPYRIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | ALOX5 2347/4885LMNA 4304/4885CYP1A2 1388/4885 |
| US-20090012079-A1 | Triazolopyridine Compounds | MAPKAPK5, MAPK1, MAPK4 | ALOX5 2585/4885LMNA 4171/4885CYP1A2 703/4885 |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | ALOX5 1580/4885LMNA 857/4885CYP1A2 2081/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | ALOX5 56/4885LMNA 4198/4885CYP1A2 137/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | ALOX5 2573/4885LMNA 4261/4885CYP1A2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.